BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Prognosis
101 results:

  • 1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL-mediated leukemia.
    Nakamura A; Masuya M; Shinmei M; Tawara I; Nosaka T; Ono R
    Blood Adv; 2024 May; 8(9):2193-2206. PubMed ID: 38452334
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic Lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry.
    Li S; Zheng S; Huang X; Zhang W; Liu F; Cao Q
    Fetal Pediatr Pathol; 2024; 43(2):111-122. PubMed ID: 38213180
    [No Abstract]    [Full Text] [Related]  

  • 4. Clinical whole-genome sequencing and FISH identify two different fusion partners for NUP98 in a patient with acute myeloid leukemia: A case report.
    Mojarad BA; Crees ZD; Schroeder MC; Xiang Z; Vader J; Sina J; Jacoby M; Frater JL; Duncavage EJ; Spencer DH; Lavine K; Neidich JA; Amarillo I
    Cancer Genet; 2024 Jan; 280-281():1-5. PubMed ID: 38056049
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models.
    Ge G; Zhang P; Sui P; Chen S; Yang H; Guo Y; Rubalcava IP; Noor A; Delma CR; Agosto-Peña J; Geng H; Medina EA; Liang Y; Nimer SD; Mesa R; Abdel-Wahab O; Xu M; Yang FC
    J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37917239
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Acute leukemia with cytogenetically cryptic fgfr1 rearrangement and lineage switch during therapy: A case report and literature review.
    McKeague SJ; O'Rourke K; Fanning S; Joy C; Throp D; Adams R; Harvey Y; Keng TB
    Am J Clin Pathol; 2024 Feb; 161(2):197-205. PubMed ID: 37855739
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia.
    Huang W; Zheng S; Wang Q; Zhao N; Long Z
    Sci Rep; 2023 Sep; 13(1):15658. PubMed ID: 37730831
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.
    Elcheva IA; Gowda CP; Bogush D; Gornostaeva S; Fakhardo A; Sheth N; Kokolus KM; Sharma A; Dovat S; Uzun Y; Schell TD; Spiegelman VS
    Front Immunol; 2023; 14():1224516. PubMed ID: 37503349
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to fgfr1 inhibitors through amino acid metabolic reprogramming.
    Zhang ZJ; Wu QF; Ren AQ; Chen Q; Shi JZ; Li JP; Liu XY; Zhang ZJ; Tang YZ; Zhao Y; Yao NN; Zhang XY; Liu CP; Dong G; Zhao JX; Xu MJ; Yue YQ; Hu J; Sun F; Liu Y; Ao QL; Zhou FL; Wu H; Zhang TC; Zhu HC
    Acta Pharmacol Sin; 2023 Nov; 44(11):2282-2295. PubMed ID: 37280363
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.
    Sousa LG; McGrail DJ; Lazar Neto F; Li K; Marques-Piubelli ML; Ferri-Borgogno S; Dai H; Mitani Y; Spardy Burr N; Cooper ZA; Kinneer K; Cortez MA; Lin SY; Bell D; El Naggar A; Burks J; Ferrarotto R
    Clin Cancer Res; 2023 Aug; 29(16):3162-3171. PubMed ID: 37256648
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. HIF1α-mediated transactivation of WTAP promotes AML cell proliferation via m
    Shao YL; Li YQ; Li MY; Wang LL; Zhou HS; Liu DH; Yu L; Lin J; Gao XN
    Leukemia; 2023 Jun; 37(6):1254-1267. PubMed ID: 37087529
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
    Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
    Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
    Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
    Nat Commun; 2023 Feb; 14(1):809. PubMed ID: 36781850
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
    Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
    Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A truncated derivative of fgfr1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
    Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
    Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.
    Huang M; Dong W; Xie R; Wu J; Su Q; Li W; Yao K; Chen Y; Zhou Q; Zhang Q; Li W; Cheng L; Peng S; Chen S; Huang J; Chen X; Lin T
    Cancer Commun (Lond); 2022 May; 42(5):447-470. PubMed ID: 35434944
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. GRWD1-WDR5-MLL2 Epigenetic Complex Mediates H3K4me3 Mark and Is Essential for Kaposi's Sarcoma-Associated Herpesvirus-Induced Cellular Transformation.
    Wei S; Lu S; Liang L; Wang X; Li W; Li T; Chen L; Ju E; Zhang X; Lai Z; Huang Y; Lu X; Gao SJ
    mBio; 2021 Dec; 12(6):e0343121. PubMed ID: 34933446
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Expression characteristic of
    Zhang W; Zhang L; Qian J; Lin J; Chen Q; Yuan Q; Zhou J; Zhang T; Shi J; Zhou H
    Bioengineered; 2021 Dec; 12(2):11987-12002. PubMed ID: 34787059
    [No Abstract]    [Full Text] [Related]  

  • 19. Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.
    Sweha SR; Chung C; Natarajan SK; Panwalkar P; Pun M; Ghali A; Bayliss J; Pratt D; Shankar A; Ravikumar V; Rao A; Cieslik M; Wilder-Romans K; Scott AJ; Wahl DR; Jessa S; Kleinman CL; Jabado N; Mackay A; Jones C; Martinez D; Santi M; Judkins AR; Yadav VN; Qin T; Phoenix TN; Koschmann CJ; Baker SJ; Chinnaiyan AM; Venneti S
    Sci Transl Med; 2021 Oct; 13(615):eabf7860. PubMed ID: 34644147
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia.
    Zhang LY; Jin Y; Xia PH; Lin J; Ma JC; Li T; Liu ZQ; Xiang HL; Cheng C; Xu ZJ; Zhou H; Qian J
    Cancer Med; 2021 Nov; 10(21):7831-7846. PubMed ID: 34562306
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.